Strong Abraxane Cancer Data Promised, But Abraxis Mum On Spin-Off Details
This article was originally published in The Pink Sheet Daily
Veteran Merck scientist recruited for personalized-medicine push.
You may also be interested in...
Early-stage pipeline could garner licensing deals as clinical work proceeds, with peak burn year ahead.
Pharmaceutical group to proceed as an independent developer of cancer, infectious disease therapies.
Abraxis CEO says the separation will allow the research business to focus more on personalized medicine.